Surrozen (SRZN) Net Margin (2024 - 2026)

Surrozen (SRZN) posted quarterly Net Margin of 650.04% for Q1 2026, up 81029.0% year-over-year from N/an in Q1 2025, and up 62.08% quarter-over-quarter from 1714.2% in Q4 2025.

Surrozen (SRZN) Net Margin (2024 - 2026) Analysis & Trends

Surrozen's Net Margin history runs 3 years deep, the most recent figure standing at 650.04% for Q1 2026.

  • In Q1 2026, Net Margin rose 81029.0% year-over-year to 650.04%; the TTM figure through Mar 2026 stood at 1219.48% (down 35034.0% YoY), while the FY2025 annual figure was 1493.64%, down 78279.0% from the prior year.
  • Net Margin for Q1 2026 stood at 650.04%, up from 1714.2% in the prior quarter.
  • The five-year high for Net Margin was 2218.51% in Q2 2025, with the low at 9175.73% in Q4 2024.
  • The 3-year median for Net Margin is 1460.33% (2025), against an average of 2583.47%.
  • Peak annual rise in Net Margin reached 746152 bps in 2025, while the deepest fall reached 727386 bps in 2025.
  • Surrozen's Net Margin stood at 9175.73% in 2024, then surged by 81 bps to 1714.2% in 2025, then soared by 62 bps to 650.04% in 2026.
  • Business Quant data shows SRZN's Net Margin at 650.04% in Q1 2026, 1714.2% in Q4 2025, and 7288.2% in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Margin (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 32.99%
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 30.23%
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 30.33%
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 13.90%
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 30.98%
7 Royalty Pharma 33.72 Bn 35.84 Bn - 12.09%
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 12.74%
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -3.12%
10 Surrozen 281.63 Mn 281.63 Mn - 640.76%

Historic Data

Download Data
DateValue
Jun 30, 2026 640.76%
Mar 31, 2026 -650.04%
Dec 31, 2025 -1,714.20%
Sep 30, 2025 -7,288.20%
Jun 30, 2025 2,218.51%
Mar 31, 2025 -1,460.33%
Dec 31, 2024 -9,175.73%
Sep 30, 2024 -14.34%